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Abstract: Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological
processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their
ligands can promote tumor growth and angiogenesis in many tumor types, including lung or
breast cancer. The development of FGF1-targeting molecules with potential implications for the
therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment
of cancer. In this study we have used phage display selection to find scFv antibody fragments
selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones
were expressed and characterized with regard to their binding to FGF1 and ability to interfere with
FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format,
as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc
exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity
of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel
FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective
cancer therapy.
Keywords: scFv antibody fragments; scFv-Fc fusions; phage display; FGF1; FGFR; ligand trap; tumor
targeting treatment; growth factor receptor targeting
1. Introduction
Deregulated growth factor’s receptors play a fundamental role in the development and
progression of a variety of human cancers, and are one of the intensively studied therapeutic targets.
We focused on fibroblast growth factor 1 (FGF1) and its receptor (FGFR), a member of receptor tyrosine
kinase family (RTKs), as its overexpression or aberrant activation has been reported in breast [1,2],
lung [3], and gastric cancers [4]. Moreover, the importance of FGFR-targeted therapy lies also in
the interplay and complementarity between different growth factor receptors and their downstream
signaling—it has been reported that for EGFR, VEGFR, and FGFR, inhibition of one of them leads
to compensation in signaling from the remaining ones [5,6]. Additionally, angiogenic properties of
FGFRs may further facilitate cancer progression and tumor growth.
Based on the role of the FGF1–FGFR signaling axis in cancer, a number of novel drugs targeting
this pathway have been developed and are recently undergoing preclinical and clinical trials in various
FGFR-related tumors [7,8]. Current FGFR activation inhibitors can be divided into three groups:
small molecule receptor tyrosine kinase inhibitors (TKIs), antagonistic antibody or peptide inhibitors,
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and FGF ligand traps. TKIs suffer from relatively low specificity towards individual growth factor
receptors and thus present a risk of increased side-effects when administered clinically [9].
FGFR-targeted antibodies and peptide inhibitors act by binding to the extracellular domain of
the receptor and competing for binding with its ligand, a strategy that proved to be effective i.e.,
in the clinical use of trastuzumab blocking HER2 receptor [10]. Several antibodies targeting different
members of FGFR family have been developed [11]. For example, anti-FGFR2 antibodies displayed
high efficacy in mice against FGFR-overexpressing breast cancer (GP369 and GAL-FR22) and gastric
cancer (GAL-FR21) xenografts [12–14]. MFGR1877S, an anti-FGFR3 antibody, showed very promising
results in preclinical studies, but tested in phase I clinical study for urothelial cancers and multiple
myeloma yielded equivocal results [15].
The last group of molecules disrupting FGFR signaling are ligand traps that sequester growth
factor ligand precluding its binding to the receptor, and thereby inhibiting FGFR activation.
Ligand traps are based either on FGFR fragments acting as decoy molecules [16,17], peptides derived
from natural FGF binders [18,19], or anti-FGF antibodies. Currently known anti-FGF antibodies have
been developed mostly against FGF2, either generated in mice [20] or selected by screening libraries of
formats such as scFv [21] and later reformatted to diabody [22]. Besides FGF2, mouse antibodies have
been generated also against FGF1, FGF8b, and FGF23 and were shown to inhibit growth of breast and
prostate cancer cells [23–25].
With fibroblast growth factors and their receptors being increasingly studied and taking into
account their role in cancer-directed therapy, in this study we report the development of specific human
antibody fragments, targeting fibroblast growth factor 1, that act as FGF1 ligand traps. The binders
in scFv format were selected from Tomlinson I and J libraries, fully characterized, and reformatted
to bivalent scFv-Fc fusions. Their effectiveness was evaluated by detailed binding tests, as well
as investigating their ability to inhibit FGF1-induced cell proliferation. Our results indicate that
developed scFvs and scFvs-Fc reduce the in vitro proliferation of FGFR1-expressing mouse fibroblast
NIH/3T3cells, FGFR1-transfected BaF3 cells, and most importantly G-292 human osteosarcoma
cancer cells.
2. Results
2.1. Selection of Human scFv Antibody Fragments Specific for FGF1
FGF1-specific scFv antibody fragments were selected from the Tomlinson I + J libraries. In addition
to the actual selection of scFvs binding FGF1, each round of selection included counterselection with
FGF1 mutant characterized by dramatically reduced affinity to FGFR (FGF1 Y94A/N95A) [26]. The use
of this protein in the counterselection step enabled significant depletion of phage clones presenting
scFv fragments recognizing receptor-binding deficient FGF1 variant and increased the probability that
clones selected afterwards against wild-type FGF1 will bind to the region involved in the interaction
with the receptor. In the third round of selection additional competitive elution performed with
ECD_FGFR1-Fc was used to obtain a pool of phages presenting scFvs more likely to be specific for
the receptor interaction region on FGF1. After three rounds of panning, bacterial supernatants of 368
randomly picked clones were screened for FGF1 binding and 51 FGF1-specific clones were identified
based on signal intensity in ELISA assay with immobilized FGF1 (Figure 1a–d). Next, the clones were
further validated for binding to FGF1 with the use of biolayer interferometry (BLI). Among tested
clones, 30 showed favorable binding profiles (Figure 1e–h) and their nucleotide sequences were
analyzed, revealing that several clones shared the same sequence. The overall analysis enabled us to
distinguish 10 unique amino acid sequences of FGF1-binding scFvs.
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Figure 1. Analysis of anti-FGF1 scFv clones selected from Tomlinson I and J libraries. (a,b) ELISA 
signal (green) for the clones eluted using ECD_FGFR1-Fc and (c,d) triethylamine. Clones giving the 
highest signal (marked in pink) were selected for further analysis. Anti-BSA clone (PC, indicated in 
blue) served as a positive control. Grey bars represent negative controls; and (e–h) BLI screening of 
scFv clones bacterial supernatants against FGF1 immobilized on the sensor surface (binding signal 
shown in green). Clones with the best binding profiles (indicated with pink arrow) were chosen for 
further testing. All scFv names originate from the 96-well plate location of the picked clone. 
2.2. Purification of the Generated FGF1-Specific scFvs 
We have chosen three scFv variants (named: scFvA, scFvC, and scFvD), based on their FGF1-
binding properties and distinct amino acid sequences in the CDR2 and CDR3 loops of the heavy and 
light antibody chains, that are particularly important in making contacts with the antigen. The scFvs 
were expressed in HB2151 E. coli cells, and efficiency of their production varied from 3.2 to 29.7 mg 
from one liter of bacterial culture (Table S1). The proteins were purified using Protein A affinity 
chromatography. Purified scFv fragments were analyzed by gel electrophoresis under reducing 
conditions, followed by Coomassie brilliant blue staining and anti-c-myc Western blotting (Figure 2a,b). 
The calculated molecular weights of the recombinant proteins were confirmed using MALDI-MS 
analysis (Figure 2c). All scFv fragments showed similar purification results. 
Figure 1. Analysis of anti-FGF1 scFv clones selected from Tomlinson I and J libraries. (a,b) ELISA
signal (green) for the clones eluted using ECD_FGFR1-Fc and (c,d) triethylamine. Clones giving the
highest signal (marked in pink) were selected for further analysis. Anti-BSA clone (PC, indicated in
blue) served as a positive control. Grey bars represent negative controls; and (e–h) BLI screening of
scFv clones bacterial supernatants against FGF1 immobilized on the sensor surface (binding signal
shown in green). Clones with the best binding profiles (indicated with pink arrow) were chosen for
further testing. All scFv names originate from the 96-well plate location of the picked clone.
2.2. Purification of the Generated FGF1-Specific scFvs
We have chosen three scFv variants (named: scFvA, scFvC, and scFvD), based on their
FGF1-binding properties and distinct amino acid sequences in the CDR2 and CDR3 loops of the
heavy and light antibody chains, that are particularly important in making contacts with the antigen.
The scFvs were expressed in HB2151 E. coli cells, and efficiency of their production varied from 3.2
to 29.7 mg from one liter of bacterial culture (Table S1). The proteins were purified using Protein A
affinity chromatography. Purified scFv fragments were analyzed by gel electrophoresis under reducing
conditions, followed by Coomassie brilliant blue staining and anti-c-myc Western blotting (Figure 2a,b).
The calculated molecular weights of the recombinant proteins were confirmed using MALDI-MS
analysis (Figure 2c). All scFv fragments showed similar purification results.
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Figure 2. scFv protein expression and purification at an example of scFvC. (a) Coomassie brilliant blue 
staining after SDS-PAGE analysis; (b) representative immunoblotting (IB) analysis of scFv purification 
process. The membrane was stained with anti-c-myc antibodies and proper HRP-conjugated secondary 
antibodies; and (c) the exemplary mass spectrometry spectrum with the highest peak originating from 
the monomeric fraction of the scFv with the expected molecular mass. Minor peak corresponding to 
the molecular weight of the covalent dimer was also detected. 
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a high number of FGF1 NH signals were perturbed upon titration of 15N FGF1 with the scFvs (Figure 3a). 
scFv-induced changes were mostly detected by the broadening of the NMR signals and reduction of 
signal intensities, indicating complex formation. Quantification of scFvs binding to FGF1 was not 
possible, since a large number of FGF1 NH signals disappeared upon addition of scFv, with complete 
lack of signal in the HMQC spectra with higher than equimolar amounts of scFv. Formed FGF1-scFv 
complex is approximately twice the molecular weight of free FGF1, and thus extensive peak 
broadening leads to loss of signals. The HMQC NMR results are further supported by the 1H NMR 
spectra (Figure 3b). 
 
Figure 3. NMR binding assay. (a) Exemplary 15N-1H HMQC NMR spectra of 15N FGF1 (red) and the 
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Figure 2. scFv protein expression and purification at an example of scFvC. (a) Coomassie brilliant blue
staining after SDS-PAGE analysis; (b) representative immunoblotting (IB) analysis of scFv purification
process. The membrane was stained with anti-c-myc antibodies and proper HRP-conjugated secondary
antibodies; and (c) the exemplary mass spectrometry spectrum with the highest peak originating from
the ono eric fraction of the scFv with the expected olecular ass. inor peak corresponding to
the olecular eight of the covalent di er as also detected.
2.3. Characterization, Analysis of Binding to FGF1 and Kinetic Parameters of the Selected scFvs
Binding of the antibody fragments (scFvs A, C, and D) to the FGF1 protein was analyzed by
the SAR-by-NMR method using the 15N labeled FGF1. In all recorded NMR spectra the chemical
shifts of a high number of FGF1 NH signals were perturbed upon titration of 15N FGF1 with the
scFvs (Figure 3a). scFv-induced changes were mostly detected by the broadening of the NMR signals
and reduction of signal intensities, indicating complex formation. Quantification of scFvs binding
to FGF1 was not possible, since a large number of FGF1 NH signals disappeared upon addition of
scFv, with complete lack of signal in the HMQC spectra with higher than equimolar amounts of scFv.
Formed FGF1-scFv complex is approximately twice the molecular weight of free FGF1, and thus
extensive peak broadening leads to loss of signals. The HMQC NMR results are further supported by
the 1H NMR spectra (Figure 3b).
To test if the generated scFvs bind specifically to properly folded FGF1, we performed ELISA
assay with immobilized native FGF1. Thermally denatured FGF1 and native FGF2 were used as
controls for scFv binding specificity (Figure 4). We confirmed that all three antibody fragments (scFvs
A, C, and D) recognized native FGF1, without binding structurally similar FGF2.
The affinity to FGF1 and the parameters of the analyzed scFvs were determined with BLI kinetic
measurements. We observed strong binding of the antibody fragments to FGF1 chemically immobilized
on the sensor (Figure 5a–c). The data were fitted using a bivalent analyte interaction model, due to
the fact that the antibody fragments can partly associate to form a mixture of dimers and monomers.
The calculation of the kinetic parameters revealed that the selected scFvs displayed high binding
affinities with KD values in the nano- and micromolar range, as summarized in Table 1.
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F F1-scFvA complex (blue) (the protein/ligand ratio 1:1); and (b) representative 1D 1H NMR
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Table 1. Kinetic constants of the generated anti-FGF1 scFvs. 
Protein KD1 [M] ka1 [M−1s−1] kd1 [s−1] KD2 [M] ka2 [M−1s−1] kd2 [s−1] 
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To verify if the regions within FGF1 to which selected monoclonal antibody fragments bind are 
distinct or overlapping, epitope binning was performed with the use of BLI method. In a series of BLI 
measurements, pairs of scFvs were tested for binding to chemically immobilized FGF1. Subsequent 
incubation of FGF1 with different scFv was used to verify if scFvs were able to bind FGF1 simultaneously 
at distinct epitopes, or if the first scFv precluded the second scFv from binding to the ligand (Figure 6a,b). 
Figure 4. ELISA cross-reactivity analysis. Purified scFv fragments were tested for specificity against
native FGF1 with thermally denatured FGF1 (den FGF1) and FGF2 serving as negative controls.
A non-FGF1-specific scFv clone was used as an additional negative control (NC). The error bars show
standard deviation.
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Figure 5. Binding profiles of the selected scFv fragments to FGF1. (a–c) Serial twofold dilutions of the
scFvs were analyzed for interaction with chemically immobilized FGF1, and dissociation measured in
kinetics buffer (KB).
To verify if the regions with FGF1 to which s lect d monoclonal antibody fragments bind are
distinct or overlapping, epitope binning was performed with the use of BLI method. In a series of BLI
measurements, pairs of scFvs were tested for binding to chemically immobilized FGF1. Subsequent
incubation of FGF1 with different scFv was used to verify if scFvs were able to bind FGF1 simultaneously
at distinct epitopes, or if the first scFv precluded the second scFv from binding to the ligand (Figure 6a,b).
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As a result of the study two independent binding epitopes on FGF1 were distinguished. We found
that among three tested scFvs, two of them: scFvC and scFvD share a binding site on FGF1 and
compete in binding it, and scFvA binds non-overlapping epitopes on the ligand. In the next step
we verified if the scFvs were able to compete with FGFR1 for FGF1 binding. For this approach we
used immobilized recombinant ECD_FGFR1-Fc protein and analyzed binding of premixed scFvs-FGF1
complexes, with scFvs or FGF1 only, serving as controls. The experiments revealed that the generated
antibody fragments decrease the ability of FGF1 to bind to its receptor (Figure 6c–f).
Table 1. Kinetic constants of the generated anti-FGF1 scFvs.
Protein KD1 [M] ka1 [M−1s−1] kd1 [s−1] KD2 [M] ka2 [M−1s−1] kd2 [s−1]
scFvA 1.41 × 10−6 2.98 × 104 8.32 × 10−2 3.32 × 10−5 1.35 × 101 4.49 × 10−4
scFvC 9.21 × 10−6 9.60 × 103 4.19 × 10−2 2.05 × 10−6 2.13 × 102 4.36 × 10−4
scFvD 1.21 × 10−6 2.14 × 104 2.58 × 10−2 1.35 × 10−5 6.93 × 101 1.35 × 10−5
Int. J. Mol. Sci. 2018, 19, x  6 of 17 
 
As a result of the study two independent binding epitopes on FGF1 were distinguished. We found 
that among three tested scFvs, two of them: scFvC a d scFvD share a binding site on FGF1 and 
compete in binding it, and scFvA binds non-overlapping epitopes on the ligand. In the next step we 
verified if the scFvs were able to compete with FGFR1 for FGF1 binding. For this approach we used 
immobilized recombinant ECD_FGFR1-Fc protein and analyzed binding of premixed scFvs-FGF1 
complexes, with scFvs or FGF1 only, serving as controls. The experiments revealed that the generated 
antibody fragments decrease the ability of FGF1 to bind to its receptor (Figure 6c–f). 
 
Figure 6. Epitope binning of selected scFvs with FGF1 and ECD_FGFR1-Fc. (a,b) Representative 
sensograms showing binding of subsequent scFvs to FGF1 immobilized on the sensor. scFvC blocking 
the ability of scFvD to bind FGF1, and scFvA binding FGF1 in the presence of scFvD; (c–e) Binding of 
FGF1 (blue), FGF1-scFv complex (green), and scFv (grey) to ECD_FGFR1-Fc immobilized on the 
sensor; (f) Percent of blocking of FGF1 binding to ECD_FGFR1-Fc by the selected antibody fragments. 
The error bars indicate standard deviation. 
2.4. Reformatting of the scFv Antibody Fragments to the scFv-Fc Fusions 
To increase the size and valency of the selected antibody fragments and therefore improve their 
avidity, we cloned scFvs A, C, and D into the scFv-Fc format. The Fc-fusions were designed by introducing 
the CH2 and CH3 domains of human IgG1 to the scFv constructs. scFv-Fc fusion proteins were 
expressed using transient transfection in CHO-S cells, resulting in moderate to high yields of 
recombinant protein expression (Table S2). Protein production was followed by a single-step affinity 
chromatography purification on Protein A resin with SDS-PAGE and Coomassie blue staining, anti-
Fc Western blotting, and mass spectrometry analysis (Figure 7a–c). All scFvs-Fc showed the same 
purity level, estimated to be above 95%. 
Figure 6. Epitope binning of selected scFvs ith FGF1 and ECD_FGFR1-Fc. (a,b) Representative
sensogra s sho ing binding of subsequent scFvs to F F1 i obilized on the sensor. scFvC blocking
the ability of scFv to bind FGF1, and scFvA binding FGF1 in the presence of scFvD; (c–e) Binding
of FGF1 (blue), FGF1-scFv complex (green), and scFv (grey) to _F F 1-Fc i obilize o t e
se s r; (f) erce t f l c i f 1 i i t _ 1- c t e selecte a ti fra e ts.
rr r rs i ic te sta ar eviation.
2.4. Reformatting of the scFv Antibody Fragments to the scFv-Fc Fusions
To increase the size and valency of the selected antibody fragments and therefore improve their
avidity, we cloned scFvs A, C, and D into the scFv-Fc format. The Fc-fusions were designed by
introducing the CH2 and CH3 domains of human IgG1 to the scFv constructs. scFv-Fc fusion proteins
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were expressed using transient transfection in CHO-S cells, resulting in moderate to high yields of
recombinant protein expression (Table S2). Protein production was followed by a single-step affinity
chromatography purification on Protein A resin with SDS-PAGE and Coomassie blue staining, anti-Fc
Western blotting, and mass spectrometry analysis (Figure 7a–c). All scFvs-Fc showed the same purity
level, estimated to be above 95%.Int. J. Mol. Sci. 2018, 19, x  7 of 17 
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Table 2. Kinetic constants of the anti-FGF1 scFvs-Fc.
Protein KD1 [M] ka1 [M−1s−1] kd1 [s−1] KD2 [M] ka2 [M−1s−1] kd2 [s−1]
scFvA-Fc 4.24 × 10−7 8.81 × 104 3.72 × 10−2 7.27 × 10−6 1.64 × 102 1.19 × 10−3
scFvC-Fc 5.22 × 10−7 7.24 × 104 3.78 × 10−2 8.81 × 10−6 8.12 × 101 7.16 × 10−4
scFvD-Fc 3.46 × 10−7 1.32 × 105 4.56 × 10−2 6.52 × 10−5 5.13 × 101 3.34 × 10−3
2.6. Blocking of FGF1-dependent Cell Proliferation
To explore the effects of generated antibody fragments on FGF1 mitogenic activity,
FGF1-dependent cell proliferation was examined. The mouse fibroblast NIH/3T3 cells were treated
with selected scFvs and scFvs-Fc without (Figure S1a) and in the presence of FGF1 and heparin
(Figure 9a). By trapping FGF1, five selected antibody fragments—scFvs C and D, together with scFvs
A-Fc, C-Fc, and D-Fc, efficiently inhibited NIH/3T3 cell proliferation, from 22 to 91%. Generated
antibody fragments were further tested in FGFR1-expressing BaF3-R1 cells, in which scFvs-Fc also
displayed significant activity (cell proliferation inhibition from 62 to 100%, as shown in Figure 9b),
similar to the ECD_FGFR1-Fc ligand trap control (Figure S1b). The lack of effect for the scFvs may
result from overall lower stability of this format in a long-term assay. This may also be the case for
scFvA tested in NIH/3T3 cells, as it inhibits cell proliferation only as the Fc fusion. Finally, we also
achieved a strong antimitogenic activity of the generated antibody fragments on G-292, FGFR1-positive,
human osteosarcoma cancer cell line (Figure 9c), confirming their ability to efficiently bind FGF1 and
preclude its binding to FGFR1 in in vitro model, without having any effect in the absence of FGF1
(Figure S1c). The results obtained for the cancer cell line were consistent with the data for fibroblast cells,
showing the most significant effect for scFvs B and C, together with all generated scFvs-Fc. Similarly
to NIH/3T3 cells, all antibody fragments except scFvA, showed complete proliferation inhibition.
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3. Discussion
FGF1 is a strong mitogenic agent, important in angiogenesis, tissue regeneration, and the
inflammation processes [8,27]. The role of FGF1 signaling in cancer is widely studied [6,19,28,29].
Preclinical and clinical evidences indicate that blocking aberrant FGF/FGFR signaling may represent
a promising strategy for the therapy of human cancers [30]. Efforts targeting this pathway have led
to the development of numerous small molecule FGFR inhibitors with wide implications for cancer
therapy [9]. These tyrosine kinase inhibitors show varied effects in clinical trials, with the response
being highly dependent on tumor genetic characteristics [31].
Another group of therapeutics consists of antibodies and FGF traps that represent a novel
class of compounds with promising therapeutic features. Their advantages over the TKIs are low
dosage and toxicity, high activity, and amino acids being their metabolic end products. There are
several monoclonal antibody fragments currently being investigated in preclinical and early phase
development studies [30,32]. The examples include: GP369, an antibody specific for FGFR2,
or BAY1187982—an anti-FGFR2 antibody-drug conjugate, that both have shown successful results on
gastric and breast cancer models [12,33]. Another drug, MFGR1877S, a monoclonal antibody targeting
FGFR3 has demonstrated promising activity in preclinical models of urothelial carcinoma [15], although
failed to work in clinical studies of multiple myeloma treatment.
Ligand traps, on the other hand, target soluble growth factors, and by sequestering them
prevent activation of FGFRs on cancerous cells. This group is represented by natural FGFs binders,
such as heparin, thrombospondin-1 (TSP-1), or longpentraxin-3 (PTX-3) [34], as well as soluble decoy
FGFRs [17,35] and synthetic molecules able to bind FGFs, e.g., heparin-like polyanionic molecules [36]
and anti-FGF1 antibodies [20–22]. To date, among the listed FGF traps, a promising molecule is FP-1039,
a soluble FGFR1-Fc fusion protein that binds almost all FGFs, and thus inhibits growth of different
tumor cell lines, including lung and endometrial cancer, as well as mesothelioma cell lines [35,37].
FP-1039 inhibits in vivo growth of different tumor models, shows low toxicity, and is currently tested
in phase I clinical trial [16].
Among anti-FGF antibodies developed for therapeutic applications, FGF2 is the most commonly
chosen target for selection of antibodies or antibody fragments [20–22], but there are also few reports on
anti-FGF1 [24,38], anti-FGF8b [23], and anti-FGF23 [25]. Regarding antibodies binding FGF1, there is
a scFv1C9 developed by the group of Xiao-Juan Zhu [24,38,39]. This small antibody is based on
hybridoma derived from mouse immunized with FGF1 and inhibits growth of breast and glioma
tumors in vitro and in vivo. Our experimental approach presented here for the identification of
FGF1-binding scFv variants differs significantly, as they were selected from scFv library with the use
of phage display. Additionally, the binders were counterselected against receptor-binding deficient
FGF1 mutant to maximize the probability of selected scFv clones binding in the FGFR-FGF1 interface
and thus interrupting receptor–ligand interaction.
In this study we developed a panel of antibody fragments capable of binding and neutralizing the
activity of FGF1. We have selected this target, as the activity of FGF1 is related to the activation of all
four FGF receptor isoforms [40], thus the potential of the generated antibody fragments can be more
widely exploited. The binders were obtained by optimizing a well-established selection procedure
from Tomlinson I and J libraries [41]. scFv—a widely used antibody format has several advantages
over the full-length monoclonal antibodies, such as easier production, or improved penetration into
tumor tissue [42]. Three scFv clones, named scFvA, C, and D, showing best binding properties,
were selected for further experiments. First, we validated scFv binding to FGF1 by SAR-by-NMR
measurements. The SAR-by-NMR method is based on monitoring the chemical shift changes in protein
amide backbone resonances upon addition of an interacting agent [43–45]. For all tested scFvs we have
observed changes in NH chemical shifts of 15N-FGF1, mostly by the broadening of the NMR signals and
reduction of signal intensities due to complex formation, implying an intermediate chemical exchange
rate on the NMR timescale [44–46]. Moreover, generated antibody fragments showed high selectivity
against FGF1, with micro- and nanomolar dissociation constants, as established by BLI measurements.
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In the next stage of our study we have reformatted the scFv fragments to the scFc-Fc fusion
format. In line with our expectations and previous experience, this conversion resulted in significant
improvement of the affinity to FGF1, lowering the dissociation constants by 3- to 17-fold. Moreover,
when considering the future therapeutic applications, the scFv-Fc format displays several advantages,
that include higher valency and larger size of the antibody fragments. It results in prolonged circulation
half-life, bivalent binding, and possessing the ability to induce antibody-dependent cell-mediated
cytotoxicity [47].
To explore the value of generated FGF1 traps as therapeutic agents, we determined their capacity
to inhibit the FGF1-induced proliferation of FGFR-expressing cells. We performed cell proliferation
assays on fibroblast NIH/3T3 cells, which are known to express FGFR1 and are the most responsive
cells with regard to FGF1-induced mitogenic effects, and therefore optimal for proliferation assays.
Additionally, we have tested BaF3-R1 pro B cells, overexpressing FGFR1 with Ig-like domain III in
c splice form [48]. BaF3-FGFR1 cells respond well to FGF1 stimulation (similarly to NIH/3T3) and
are therefore a good model of FGFR-overexpressing cancers for in vitro proliferation assays. In the
next step we have examined the effect of selected antibody fragments on FGF1 trapping in human
osteosarcoma G-292 cancer cell line. We demonstrated that all generated scFv-Fc fusions potently
suppressed the FGF1-induced cell proliferation of all: fibroblast NIH/3T3 cells, transfected BaF3-R1
cells, and FGFR1-expressing G-292 cells. We did not observe antiproliferative activity for scFvA in the
NIH/3T3 and G-292 models, and for the scFv fragments A, C, and D in the BaF3-R1 cells, presumably
due to a possible lower stability of scFv format compared to Fc-fusions. Yet, two of the tested scFvs (C
and D) have shown inhibitory effect on NIH/3T3, and G-292 proliferation.
In general, generated antibody fragments in Fc-fusion format effectively neutralized the mitogenic
activity of FGF1, and the level of cell proliferation showed dramatic reduction up to 100% for the
scFvA-Fc in the BaF3-R1 model, and for the majority of tested antibody fragments in the G-292 model.
Summarizing, with the use of an optimized phage display method and subsequent reformatting,
we have generated highly potent anti-FGF1 antibody fragments, exhibiting high affinity and specificity
towards the antigen. Our data clearly indicate that the developed antibody fragments acting as FGF1
ligand traps can serve as potent therapeutic agents for the treatment of FGF1-dependent cancers.
Further studies on cancer cell lines continued in in vivo xenograft models will be essential to future
development of generated anti-FGF1 molecules.
4. Materials and Methods
4.1. Proteins
4.1.1. FGF1 and FGF1 Mutant Y94A/N95A
Recombinant FGF1 (Met-Ala-FGF122−155) was produced at 37 ◦C in an E. coli BL21(DE3)pLysS
strain and purified on a heparin-sepharose CL-6B column following a described procedure [49,50].
FGF1 mutant Y94A/N95A was designed by Zakrzewska et al. [26]. The recombinant protein was
expressed and purified in the same manner as for FGF1.
4.1.2. 15N FGF1
15N-FGF1 for NMR measurements was expressed in E. coli BL21(DE3)Rosetta grown in minimal
medium containing 15N-NH4Cl as nitrogen source. 30 mL of preculture in LB medium was centrifuged,
washed, and used to inoculate minimal medium M9 with 15N-NH4Cl and 0.4% glucose. Cells were
grown at 37 ◦C to OD600 = 1.2 and induced with 0.5 mM IPTG. Protein expression was conducted
for 16 h at 30 ◦C. Protein from soluble fraction was purified on a heparin-sepharose CL-6B column
similarly to wild-type FGF1.
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4.1.3. FGF2
Recombinant, 133 amino acid truncated form of FGF2 was expressed at 25 ◦C in E. coli
BL21(DE3)pLysS and purified by affinity chromatography as described by Swiderska et al. [51].
4.1.4. ECD_FGFR1-Fc
Human IgG1 Fc fusion of the full length extracellular domain of FGFR1 (ECD_FGFR1-Fc)
expression was carried out according to Sokolowska-Wedzina et al. [52] with minor modifications.
Briefly, CHO-S cells (Invitrogen, Carlsbad, CA, USA) were cultured at 37 ◦C in a shaking incubator
at 110 rpm with 8% CO2 in PowerCHO-2CD medium (Lonza, Basel, Switzerland) supplemented
with 8 mM L-glutamine and 1× penicillin/streptomycin solution (Biowest, Riverside, MO, USA).
On the day of transfection the culture was centrifuged and cell pellet was resuspended in ProCHO4
medium (Lonza). Appropriate amount of ECD_FGFR1-Fc encoding plasmid (1.25 µg of DNA per
every 1 × 106 cells) was resuspended in 150 mM NaCl, mixed and incubated for 10 min at RT with
a proper amount of linear polyethylenimine (PEI; Polyscience, Warrington, PA, USA) and diluted in
150 mM NaCl (5 µg of PEI per each 1 × 106 cells). The final volume of the DNA and PEI solution
corresponded to 10% of the total cell suspension volume. The DNA and PEI complexes were added
to the cell solution. The transfection procedure was carried out for 4 h at 37 ◦C, 110 rpm, and 8%
CO2. After this time, the culture was diluted with an equal volume of PowerCHO-2CD supplemented
with 8 mM L-glutamine and 2× penicillin-streptomycin solution and incubated at 32 ◦C, 110 rpm,
and 8% CO2. On the second day of protein production, the CHO-S culture was supplemented with
L-glutamine to the final concentration of 4 mM. The cells were harvested on the tenth day of expression.
The purification of the ECD_FGFR1-Fc protein was performed following a described procedure,
using affinity chromatography rProtein A Sepharose Fast Flow Resin (GE Healthcare, Little Chalfront,
UK) [52].
4.2. Phage Display Selection of scFv Antibody Fragments
The selection procedure was based on a Tomlinson I and J libraries protocol [41] and was
performed as follows. The 96-well Nunc Maxi Sorp plates (Thermo Fisher Scientific, Waltham,
MA, USA) were coated overnight at 4◦ C with 100 µg/mL of FGF1 or FGF1 Y94A/N95A in PBS.
After washing and blocking with 2% MPBS (Marvel milk in PBS) the counterselection wells coated
with FGF1 Y94A/N95A were incubated with 1012 phage particles from the Tomlinson I and J libraries
(Source BioScience, Nottingham, UK), blocked with 2% MPBS, for 40 min with rotation (600 rpm)
and 80 min standing at 4 ◦C. The phage particles were then transferred to the washed and blocked
selection wells coated with FGF1 and incubated as described for FGF1 Y94A/N95A. The wells were
then washed 10 times with PBS-0.1% Tween 20 and 10 times with PBS (15 and 20 times for each buffer
for the subsequent rounds). For panning rounds 1 and 2 the bound phage was eluted with 100 mM
triethylamine (TEA) and neutralized with 1 M Tris-HCl, pH 7.2. In the third round the selected phage
particles were unbound from the ligand for 3 h by elution with 2-times molar excess of ECD_FGFR1-Fc
over the immobilized FGF1. The second elution step in this round was performed with TEA as in
the previous rounds. Propagation of phage after each round of panning was carried out as described
by Viti et al. [53] and Lee et al. [41]. The monoclonal ELISA of soluble scFv antibody fragments was
carried out according to Sokolowska-Wedzina et al. [54].
4.3. Biolayer Interferometry Screening of scFv Antibody Fragments
Bacterial supernatants containing soluble scFvs (the same samples as used for ELISA) were filtered
through 0.22 µm filters and screened for binding to FGF1 by biolayer interferometry. BLI experiments
were performed on an Octet K2 instrument (ForteBio Inc., Menlo Park, CA, USA) using amine-reactive
(AR2G) sensors. Sensor tips were hydrated for 15 min prior to use. The sensors were then activated
with a freshly prepared mixture of 20 mM EDC and 10 mM sulfo-NHS, coupled with 20 µg/mL
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FGF1 in 10 mM sodium acetate, pH 6.0, and then excess reactive esteres were blocked with 1 M
ethanolamine, pH 8.5. Amine-coupled FGF1 was then used to capture scFvs present in the filtered
bacterial supernatants. Association and dissociation from the ligand were both monitored for 180 s
each. Surfaces were regenerated with 100 mM glycine, pH 4.5, and the assay was repeated. ForteBio’s
Data Analysis 9.0 software was used for the analysis of the binding curves.
4.4. Purification and Analysis of scFv Antibody Fragments
scFv antibody fragments were prepared according to Sokolowska-Wedzina et al. [54]. Briefly,
purified pIT2 plasmids with scFv sequences were electroporated into E. coli HB2151 cells (Source
BioScience). The bacteria were grown in 2× TY media supplemented with 100 µg/mL ampicillin
and 0.1% glucose to OD600 = 0.8 and the production of protein was induced with 0.5 mM IPTG.
Cells were cultured at 30 ◦C, 180 rpm, overnight and then the cultures were harvested, centrifuged
twice at 4000 rcf, 4 ◦C for 40 min, and filtered using a Stericap PLUS bottle filter device (Merck
Millipore, Darmstadt, Germany). scFv antibody fragments were purified from the supernatants by
affinity chromatography using rProtein A Sepharose Fast Flow Resin (GE Healthcare), following
the same protocol as described previously by our group for ECD_FGFR-Fc proteins [52]. Purified
scFvs were analyzed by SDS-PAGE, Western blotting using anti-c-myc antibody, clone 9E10 (Santa
Cruz Biotechnology Inc., Dallas, TX, USA), and mass spectrometry. The molecular masses of the
proteins were verified by MALDI-TOF/TOF 4800 (Applied Biosystems, Foster City, CA, USA), using
α-cyano-4-hydroxycinnamic acid as a matrix.
4.5. Nuclear Magnetic Resonance Measurements
NMR spectra were measured for the 200 µL samples of 0.2 mM free 15N FGF1, 0.1 mM free
scFv, and 0.1–0.12 mM FGF1-scFv complex. FGF1 protein was in 25 mM Tris-HCl, pH 7.5, 2 M NaCl,
and 1 mM EDTA, and scFvs were in PBS buffer. 10% (v/v) D2O was added to the samples to provide
a lock signal. All spectra were recorded at 300 K using an Avance 600 MHz spectrometer (Bruker,
Billerica, MA, USA). 1H−15N heteronuclear correlations were obtained using the SOFAST HMQC
pulse sequence [55].
4.6. Cross-Reactivity Assay
The Nunc Maxi Sorp 96-well plates were coated overnight at 4 ◦C with 50 µg/mL of FGF1,
FGF1 previously thermally denatured by heating to 98 ◦C for 5 min, or FGF2 in PBS buffer. Next,
the wells were washed with PBS and blocked with 2% MPBS for 100 min and after second washing
with PBS, 10 µg/mL of scFvs were added to the wells and incubated for 60 min at 4 ◦C. The unbound
proteins were washed and anti-c-myc mouse monoclonal antibody, clone 9E10 (Abcam, Cambridge,
UK) was added to wells and incubated for 60 min at RT. The wells were washed with PBS and
a secondary goat anti-mouse IgG antibody conjugated with horseradish peroxidase (115-035-003,
Jackson ImmunoResearch, West Grove, PA, USA) was used. ELISA was developed using TMB liquid
substrate (Sigma-Aldrich, Saint Louis, MO, USA). The reaction was stopped with 1 M H2SO4 and the
absorbance was measured at 450 and 650 nm. The obtained absorbance values were a result of A650
background subtraction from A450.
4.7. Biolayer Interferometry Studies of FGF1 Binding Affinity
The kinetics of binding of antibody fragments to FGF1 were measured on an Octet K2 instrument
at 25 ◦C with FGF1 being immobilized on the AR2G sensor surface in the same manner as
described in 4.3. Measurements were performed in the PBS-based Kinetics Buffer (KB; ForteBio
Inc.), association and dissociation of the analyte to and from the ligand were monitored for 300 s or
180 s for scFvs and scFvs-Fc, respectively. Sensor surfaces were regenerated with 100 mM glycine, pH
4.0. All measurements were performed in duplicate. The kinetic data were fitted and analyzed with
Int. J. Mol. Sci. 2018, 19, 2470 13 of 17
the BIAevaluation 4.1 software (GE Healthcare) using a Bivalent analyte binding model [56,57] and
respective rate constants (kon and koff) and KD values were calculated.
4.8. Epitope Binning with Biolayer Interferometry
FGF1 was immobilized on AR2G sensors as described in 4.3. Measurements were performed
in the Kinetics Buffer. Amine-coupled FGF1 was used to capture first scFv at 200 nM for 180 s and
then the sensor was moved to the well with the second scFv prepared at the same concentration
and the following association was measured for further 180 s. The surface was regenerated with
100 mM glycine, pH 3.5, and the assay was repeated for another scFv-scFv pair. The measurements
were continued until all available scFv-scFv configurations were examined. For the scFv-FGFR1
epitope binning assay, ECD_FGFR1-Fc was coupled with activated AR2G sensors, as described for
FGF1 in 4.3., at 5 µg/mL in 10 mM sodium acetate, pH 5.0. FGF1 at 1 µM was preincubated with
scFv fragment at 1:1 molar ratio for 30 min, and then the ability of complexed FGF1 to bind to the
immobilized ECD_FGFR1-Fc was assessed. The sensor surface was regenerated with 100 mM glycine,
pH 2.5, and the assay was repeated for the remaining FGF1-scFv complexes. Binding of FGF1 only
and unspecific binding of scFvs to the immobilized protein was also verified. All measurements were
performed in duplicate. The binding curves were analyzed using ForteBio’s Data Analysis 9.0 software.
4.9. scFv-Fc Fusions Preparation, Purification and Analysis of the Proteins
The scFv-Fc constructs were prepared as described by Sokolowska-Wedzina et al. [54]. Briefly,
sequences encoding secretion signal peptide (SSP) and the HindIII and Kpn2I restriction sites were
introduced into the scFv DNA sequences in two PCR reactions. In the next step, amplified scFv
DNA and pLEV113-Fc expression vector (LakePharma, Belmont, CA, USA), encoding the Fc domain
of human IgG1 [52], were digested using HindIII and Kpn2I restriction enzymes (Thermo Fisher
Scientific), and then the PCR product was ligated with the vector with the use of T4 DNA ligase
(Thermo Fisher Scientific). The resulting construct, inserted into a pLEV113 expression vector, was used
to stably transfect CHO-S cells. scFv-Fc fusion proteins preceded with a secretion signal peptide were
expressed and purified using affinity chromatography following the procedure described for the
ECD_FGFR-Fc proteins [52]. The proteins were analyzed by SDS–PAGE, Western blotting using
anti-human IgG Fc-HRP-conjugated antibody (ab97225, Abcam) and mass spectrometry.
4.10. Cell Proliferation Studies
Mouse embryo fibroblast NIH/3T3 and human osteosarcoma G-292 cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA), whereas the BaF3-R1 (isoform IIIc) cell
line was provided by David M. Ornitz from Washington University (St. Louis, MO, USA). NIH/3T3
and G-292 cells were seeded in a 96-well flat-bottomed plates (VWR, Radnor, PA, USA) at a density of
1 × 104 cells/well in Dulbecco’s modified Eagle’s medium (DMEM, Biowest) supplemented with 10%
fetal bovine serum (FBS, Biowest) and 1× penicillin/streptomycin solution (Biowest), while BaF3-R1
cells were seeded in a 96-well flat-bottomed plates (VWR) at 3 × 104 cells/well in RPMI 1640 medium
(Gibco, Thermo Fisher Scientific) supplemented with 10% bovine calf serum (BCS; Sigma-Aldrich),
1× penicillin/streptomycin solution (Biowest), 50 µM β-mercaptoethanol (Sigma-Aldrich), 4 mM
L-glutamine (Biowest), and 0.5 ng/mL recombinant murine interleukin 3 (IL-3, PeproTech, Rocky Hill,
NJ, USA) and incubated at 37 ◦C in a humidified incubator with 5% CO2 for 16 h. The cells were then
washed with PBS and starved for 24 h in 80 µL/well of the same medium without the addition of FBS for
NIH/3T3 and G-292, or IL-3 for BaF3-R1, respectively. 20 µL of activation medium containing FGF1 and
heparin (Sigma-Aldrich) was added to the wells to the final concentrations of 5 ng/mL and 10 U/mL,
respectively. scFvs and scFvs-Fc in 50 µL/well were added to the wells to a final concentration of
100 µg/mL and cells were allowed to proliferate at 37 ◦C, 5% CO2 for 48 h. Cell viability was measured
using AlamarBlue or PrestoBlue reagent (Thermo Fisher Scientific), according to the manufacturer’s
directions. Fluorescence emission was measured using an EnVision Multilabel Reader (PerkinElmer,
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Waltham, MA, USA). Each sample dilution was prepared in triplicate and every experiment was
repeated on three independent plates.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/
2470/s1.
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